Browsing Tag
Vectus Biosystems Limited
2 posts
Vectus Biosystems (ASX:VBS) appoints Cardinal Health Regulatory Sciences for VB0004 FDA pathway
Vectus Biosystems has formalised its United States regulatory strategy for VB0004, but financing, clinical execution and evidence of human antifibrotic activity remain the decisive valuation tests.
Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004?
Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside?